Advice

in the absence of a submission from the holder of the marketing authorisation

anakinra (Kineret®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including:
• Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)
• Muckle-Wells Syndrome (MWS)
• Familial Cold Autoinflammatory Syndrome (FCAS)

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice91KB (PDF)

Download

Medicine details

Medicine name:
anakinra (Kineret)
SMC ID:
1116/15
Indication:
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including:
Pharmaceutical company
Swedish Orphan
BNF chapter
Musculoskeletal and joint diseases
Submission type
Non submission
Status
Not recommended
Date advice published:
07 December 2015